UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics

Journal of clinical oncology, 2009-09, Vol.27 (25), p.4103-4108

2009

Volltextzugriff (PDF)

A novel strategy for physiologically based predictions of human pharmacokinetics

Clinical pharmacokinetics, 2006-01, Vol.45 (5), p.511-542

2006

Volltextzugriff (PDF)

A Guide to Rational Dosing of Monoclonal Antibodies

Clinical pharmacokinetics, 2012-02, Vol.51 (2), p.119-135

2012

Volltextzugriff (PDF)

Pediatric Dosing of Ganciclovir and Valganciclovir: How Model‐Based Simulations Can Prevent Underexposure and Potential Treatment Failure

CPT: pharmacometrics and systems pharmacology, 2019-03, Vol.8 (3), p.167-176

2019

Volltextzugriff (PDF)

Model‐informed drug development of voxelotor in sickle cell disease: Exposure‐response analysis to support dosing and confirm mechanism of action

CPT: pharmacometrics and systems pharmacology, 2022-06, Vol.11 (6), p.698-710

2022

Volltextzugriff (PDF)

Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma

CPT: pharmacometrics and systems pharmacology, 2022-06, Vol.11 (6), p.687-697

2022

Volltextzugriff (PDF)

A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry

Drug metabolism and disposition, 2011-08, Vol.39 (8), p.1460-1467

2011

Volltextzugriff (PDF)

An Integrated Glucose-Insulin Model to Describe Oral Glucose Tolerance Test Data in Type 2 Diabetics

Journal of clinical pharmacology, 2007-10, Vol.47 (10), p.1244-1255

2007

Volltextzugriff (PDF)

Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration

British journal of clinical pharmacology, 2001-09, Vol.52 (3), p.255-264

2001

Volltextzugriff (PDF)

Optimal design for multivariate response pharmacokinetic models

Journal of pharmacokinetics and pharmacodynamics, 2006-04, Vol.33 (2), p.97-124

2006

Volltextzugriff (PDF)

Metabolism and excretion of tolcapone, a novel inhibitor of catechol‐O‐methyltransferase

British journal of clinical pharmacology, 1999-10, Vol.48 (4), p.513-520

1999

Volltextzugriff (PDF)

Abstract 378: Exploring intermittent dosing schedules for the Pan PI3K/mTor inhibitor PQR309

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.378-378

2016

Volltextzugriff (PDF)

A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure

Clinical pharmacology and therapeutics, 2010-06, Vol.87 (6), p.706-713

2010

Volltextzugriff (PDF)

Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding

Clinical cancer research, 2011-04, Vol.17 (8), p.2512-2520

2011

Volltextzugriff (PDF)

Abstract 382: Concomitant administration of acid reducing agents can impact the pharmacokinetics of the balanced pan-PI3K and mTOR inhibitor PQR309

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.382-382

2016

Volltextzugriff (PDF)

Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e14101-e14101

2016

Volltextzugriff (PDF)

Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa‐2a (40KD) plus ribavirin

British journal of clinical pharmacology, 2006-12, Vol.62 (6), p.699-709

2006

Volltextzugriff (PDF)

First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS2619-TPS2619

2018

Volltextzugriff (PDF)

Lack of Interaction between Tolcapone and Tolbutamide in Healthy Volunteers

Journal of clinical pharmacology, 2000-05, Vol.40 (5), p.544-551

2000

Volltextzugriff (PDF)

Pharmacokinetics of ribavirin in patients with hepatitis C virus

British journal of clinical pharmacology, 2006-12, Vol.62 (6), p.710-714

2006

Volltextzugriff (PDF)

COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet®)

British journal of clinical pharmacology, 1999-09, Vol.48 (3), p.449-452

1999

Volltextzugriff (PDF)

18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease

Synapse (New York, N.Y.), 2002-03, Vol.43 (3), p.201-207

2002

Volltextzugriff (PDF)

The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations

European neurology, 1997-01, Vol.38 (1), p.59-67

1997

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers

Neurology, 1998-05, Vol.50 (5 Suppl 5), p.S31

Jorga, K M

1998

Volltextzugriff (PDF)

The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin : comparison of the effect in healthy volunteers and in HIV-infected patients

European journal of clinical pharmacology, 2001-05, Vol.57 (2), p.115-121

2001

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(40)

Publikationsform

Sprache

Englisch
(46)
Spanisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(36)
Life Sciences & Biomedicine
(30)
Science & Technology
(30)
Biological And Medical Sciences
(25)
Medical Sciences
(25)
Pharmacology. Drug Treatments
(24)
Male
(23)
Pharmacology & Pharmacy
(23)
Adult
(18)
Female
(17)
Middle Aged
(15)
Nitrophenols
(14)
Pharmacokinetics
(14)
Aged
(13)
Anticonvulsants. Antiepileptics. Antiparkinson Agents
(11)
Dose-Response Relationship, Drug
(11)
Neuropharmacology
(11)
Tolcapone
(11)
Benzophenones - Pharmacokinetics
(9)
Catechol O-Methyltransferase Inhibitors
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics

A novel strategy for physiologically based predictions of human pharmacokinetics

A Guide to Rational Dosing of Monoclonal Antibodies

Pediatric Dosing of Ganciclovir and Valganciclovir: How Model‐Based Simulations Can Prevent Underexposure and Potential Treatment Failure

Model‐informed drug development of voxelotor in sickle cell disease: Exposure‐response analysis to support dosing and confirm mechanism of action

Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma

A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry

An Integrated Glucose-Insulin Model to Describe Oral Glucose Tolerance Test Data in Type 2 Diabetics

Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration

Optimal design for multivariate response pharmacokinetic models

Metabolism and excretion of tolcapone, a novel inhibitor of catechol‐O‐methyltransferase

Abstract 378: Exploring intermittent dosing schedules for the Pan PI3K/mTor inhibitor PQR309

A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure

Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding

Abstract 382: Concomitant administration of acid reducing agents can impact the pharmacokinetics of the balanced pan-PI3K and mTOR inhibitor PQR309

Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors

Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa‐2a (40KD) plus ribavirin

First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies

Lack of Interaction between Tolcapone and Tolbutamide in Healthy Volunteers

Pharmacokinetics of ribavirin in patients with hepatitis C virus

COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet®)

18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease

The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations

Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers

The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin : comparison of the effect in healthy volunteers and in HIV-infected patients

Suchergebnisse filtern